No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes : A post hoc analysis from the randomized controlled PRE-D trial. / Clemmensen, Kim K. B.; Blond, Martin B.; Amadid, Hanan; Bruhn, Lea; Vistisen, Dorte; Karstoft, Kristian; Persson, Frederik; Ried-Larsen, Mathias; Holst, Jens J.; Wewer Albrechtsen, Nicolai J.; Torekov, Signe S.; Quist, Jonas S.; Jorgensen, Marit E.; Faerch, Kristine.

I: Diabetes, Obesity and Metabolism, Bind 23, Nr. 2, 2021, s. 530-539.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Clemmensen, KKB, Blond, MB, Amadid, H, Bruhn, L, Vistisen, D, Karstoft, K, Persson, F, Ried-Larsen, M, Holst, JJ, Wewer Albrechtsen, NJ, Torekov, SS, Quist, JS, Jorgensen, ME & Faerch, K 2021, 'No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial', Diabetes, Obesity and Metabolism, bind 23, nr. 2, s. 530-539. https://doi.org/10.1111/dom.14246

APA

Clemmensen, K. K. B., Blond, M. B., Amadid, H., Bruhn, L., Vistisen, D., Karstoft, K., Persson, F., Ried-Larsen, M., Holst, J. J., Wewer Albrechtsen, N. J., Torekov, S. S., Quist, J. S., Jorgensen, M. E., & Faerch, K. (2021). No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial. Diabetes, Obesity and Metabolism, 23(2), 530-539. https://doi.org/10.1111/dom.14246

Vancouver

Clemmensen KKB, Blond MB, Amadid H, Bruhn L, Vistisen D, Karstoft K o.a. No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial. Diabetes, Obesity and Metabolism. 2021;23(2):530-539. https://doi.org/10.1111/dom.14246

Author

Clemmensen, Kim K. B. ; Blond, Martin B. ; Amadid, Hanan ; Bruhn, Lea ; Vistisen, Dorte ; Karstoft, Kristian ; Persson, Frederik ; Ried-Larsen, Mathias ; Holst, Jens J. ; Wewer Albrechtsen, Nicolai J. ; Torekov, Signe S. ; Quist, Jonas S. ; Jorgensen, Marit E. ; Faerch, Kristine. / No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes : A post hoc analysis from the randomized controlled PRE-D trial. I: Diabetes, Obesity and Metabolism. 2021 ; Bind 23, Nr. 2. s. 530-539.

Bibtex

@article{0aababd1737b4ef2a8b181abcdc71243,
title = "No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial",
abstract = "Aim: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.Materials and Methods: One-hundred and twenty individuals with overweight (body mass index >= 25 kg/m(2)) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT.Results: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.Conclusions: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.",
keywords = "exercise, glucagon, metformin, obesity, prediabetes, sodium-glucose co-transporter-2 inhibitor, COTRANSPORTER 2 INHIBITION, BETA-CELL FUNCTION, WEIGHT-LOSS, INSULIN-RESISTANCE, GLUCOSE, RESPONSES, GLP-1",
author = "Clemmensen, {Kim K. B.} and Blond, {Martin B.} and Hanan Amadid and Lea Bruhn and Dorte Vistisen and Kristian Karstoft and Frederik Persson and Mathias Ried-Larsen and Holst, {Jens J.} and {Wewer Albrechtsen}, {Nicolai J.} and Torekov, {Signe S.} and Quist, {Jonas S.} and Jorgensen, {Marit E.} and Kristine Faerch",
year = "2021",
doi = "10.1111/dom.14246",
language = "English",
volume = "23",
pages = "530--539",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes

T2 - A post hoc analysis from the randomized controlled PRE-D trial

AU - Clemmensen, Kim K. B.

AU - Blond, Martin B.

AU - Amadid, Hanan

AU - Bruhn, Lea

AU - Vistisen, Dorte

AU - Karstoft, Kristian

AU - Persson, Frederik

AU - Ried-Larsen, Mathias

AU - Holst, Jens J.

AU - Wewer Albrechtsen, Nicolai J.

AU - Torekov, Signe S.

AU - Quist, Jonas S.

AU - Jorgensen, Marit E.

AU - Faerch, Kristine

PY - 2021

Y1 - 2021

N2 - Aim: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.Materials and Methods: One-hundred and twenty individuals with overweight (body mass index >= 25 kg/m(2)) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT.Results: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.Conclusions: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.

AB - Aim: To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations in individuals with overweight and HbA1c-defined prediabetes.Materials and Methods: One-hundred and twenty individuals with overweight (body mass index >= 25 kg/m(2)) and prediabetes (HbA1c of 39-47 mmol/mol) were randomized to a 13-week intervention with dapagliflozin (10 mg once daily), metformin (850 mg twice daily), exercise (30 minutes of interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 and 120 minutes) was administered at baseline, at 13 weeks (end of intervention) and at 26 weeks (end of follow-up). Linear mixed effects models with participant-specific random intercepts were used to investigate associations of the interventions with fasting plasma glucagon concentration, insulin/glucagon ratio and glucagon suppression during the OGTT.Results: At baseline, the median (Q1; Q3) age was 62 (54; 68) years, median fasting plasma glucagon concentration was 11 (7; 15) pmol/L, mean (SD) HbA1c was 40.9 (2.3) mmol/mol and 56% were women. Compared with the control group, fasting glucagon did not change in any of the groups from baseline to the end of the intervention (dapagliflozin group: -5% [95% CI: -29; 26]; exercise group: -8% [95% CI: -31; 24]; metformin group: -2% [95% CI: -27; 30]). Likewise, there were no differences in insulin/glucagon ratio and glucagon suppression during the OGTT between the groups.Conclusions: In individuals with prediabetes, 13 weeks of treatment with dapagliflozin, metformin or exercise was not associated with changes in fasting or post-OGTT glucagon concentrations.

KW - exercise

KW - glucagon

KW - metformin

KW - obesity

KW - prediabetes

KW - sodium-glucose co-transporter-2 inhibitor

KW - COTRANSPORTER 2 INHIBITION

KW - BETA-CELL FUNCTION

KW - WEIGHT-LOSS

KW - INSULIN-RESISTANCE

KW - GLUCOSE

KW - RESPONSES

KW - GLP-1

U2 - 10.1111/dom.14246

DO - 10.1111/dom.14246

M3 - Journal article

C2 - 33146457

VL - 23

SP - 530

EP - 539

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -

ID: 252469514